Berkeley Catalyst Fund-backed gene therapy developer 4D Molecular Therapeutics withdrew its last attempt in July.

US-based gene therapy developer 4D Molecular Therapeutics (4DMT) refiled for an initial public offering on Tuesday, giving Berkeley Catalyst Fund, a venture unit aligned with University of California, the chance to exit. The company has filed to raise up to $75m in an offering on the Nasdaq Global Market, the same market where it originally…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.